InsidersTradesSigma
Vivoryon Therapeutics N.V.: directors' dealings · Netherlands · AFM
AFM:vivoryon-therapeutics-nvNL·AFMMcap 37M€Healthcare & Pharma
Explore the full insider trade history of Vivoryon Therapeutics N.V., a publicly traded company based in Netherlands. Shares are listed on NL NL, under the supervision of AFM. Operating in the Healthcare & Pharma sector, Vivoryon Therapeutics N.V. has recorded 39 insider filings. Market capitalisation: €37.2m. The latest transaction was reported on 17 April 2026 — Purchase. Among the most active insiders: F. Weber. All data is accessible without an account.
39
Insider Decl.
0
Thresholds
€2m
36 ops.
Buy Volume
€240,878
3 ops.
Sell Volume
Financial data
Analyst consensus
1 analysts7.50 €Target 7.50 €7.50 €
Valuation
PER (forward)-3.4x
P/Book10.4x
Beta1.38
Balance sheet & cash
Market cap37.2 M€
Debt / Equity2%
Profitability & ownership
ROE-140.4%
ROA-59.2%
% insiders21.5%
% institutions8.9%
Last declaration on 17 April 2026
Declarations39 total
Executives●Purchase11AFM
0150,000 shares0
Optie
AFM:192625·
Ideal exit: 12 Jan 2027 (T+270)
Executives●Purchase11AFM
0150,000 shares0
Optie
AFM:192632·
Ideal exit: 12 Jan 2027 (T+270)
Executives●Purchase23AFM
€233,144128,809 shares@ €1.810.63% mcap13.2% of flow
Gewoon aandeel
AFM:184550·
Ideal exit: 4 Sept 2026 (T+270)
Executives●Purchase11AFM
020,000 shares0
Optie
AFM:182044·
Ideal exit: 13 Jul 2026 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:176906·
Ideal exit: 27 Mar 2026 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:176907·
Ideal exit: 27 Mar 2026 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:176908·
Ideal exit: 27 Mar 2026 (T+270)
Executives●Purchase11AFM
050,000 shares0
Optie
AFM:176529·
Ideal exit: 21 Mar 2026 (T+270)
Executives●Sale23AFM
€233,144-128,809 shares@ €1.810.63% mcap13.2% of flow
Gewoon aandeel
AFM:173752·
Executives●Purchase11AFM
075,000 shares0
Optie
AFM:171766·
Ideal exit: 10 Dec 2025 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:160248·
Ideal exit: 18 Mar 2025 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:160246·
Ideal exit: 18 Mar 2025 (T+270)
Executives●Purchase11AFM
025,000 shares0
Optie
AFM:160247·
Ideal exit: 18 Mar 2025 (T+270)
Executives●Purchase11AFM
0120,000 shares0
Optie
AFM:159529·
Ideal exit: 3 Mar 2025 (T+270)
Executives●Sale22AFM
€7,734-3,867 shares@ €2.000.021% mcap100.0% of flow
Gewoon aandeel
AFM:155125·
Executives●Purchase11AFM
090,000 shares0
Optie
AFM:152998·
Ideal exit: 6 Oct 2024 (T+270)
25 of 39 declarations
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the Amsterdam Stock Exchange (XAMS).
